Disease-modifying treatment for preclinical Alzheimer’s disease (AD) may soon enter clinical practice, with trials of anti-amyloid therapies in preclinical AD underway. Learning that one is at elevated risk for developing cognitive decline due to AD could impact psychological wellbeing. We evaluated psychological wellbeing of older adults in Risk Evaluation in AD – Study of the Communication of Amyloid Neuroimaging (REVEAL-SCAN).